1. Kobayashi K, Ueno F, Bito S, et al. Development of consensus statements for the diagnosis and management of intestinal Behçet’s disease using a modified Delphi approach. J Gastroenterol 2007;42:737–745.

2. Lee HJ, Cheon JH. Optimal diagnosis and disease activity monitoring of intestinal Behçet’s disease. Intest Res 2017;15:311–317.

3. Park J, Park SJ, Park JJ, Kim TI, Cheon JH. Long-term clinical outcomes of intestinal Behçet’s disease: a 30-year cohort study at a tertiary hospital in South Korea. J Gastroenterol Hepatol 2023;38:386–392.

4. Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behçet’s disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol 2009;104:2492–2499.

5. Han M, Jung YS, Kim WH, Cheon JH, Park S. Incidence and clinical outcomes of intestinal Behçet’s disease in Korea, 2011-2014: a nationwide population-based study. J Gastroenterol 2017;52:920–928.

6. Cheon JH. Advances in management of intestinal Behçet’s disease: a perspective from gastroenterologists. J Rheum Dis 2021;28:4–16.

7. Valenti S, Gallizzi R, De Vivo D, Romano C. Intestinal Behçet and Crohn’s disease: two sides of the same coin. Pediatr Rheumatol Online J 2017;15:33.

8. Kim DH, Cheon JH. Intestinal Behçet’s disease: a true inflammatory bowel disease or merely an intestinal complication of systemic vasculitis? Yonsei Med J 2016;57:22–32.

9. Ghoshal UC, Shukla A. Malnutrition in inflammatory bowel disease patients in northern India: frequency and factors influencing its development. Trop Gastroenterol 2008;29:95–97.

10. Dong J, Chen Y, Tang Y, et al. Body mass index is associated with inflammatory bowel disease: a systematic review and meta-analysis. PLoS One 2015;10:e0144872.

11. Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol 2017;14:110–121.

12. Lin A, Micic D. Nutrition considerations in inflammatory bowel disease. Nutr Clin Pract 2021;36:298–311.

13. Einav L, Hirsch A, Ron Y, et al. Risk factors for malnutrition among IBD patients. Nutrients 2021;13:4098.

14. Neelam PB, Pal R, Gupta P, et al. Sarcopenia is common in ulcerative colitis and correlates with disease activity. Intest Res 2024;22:162–171.

15. Nagata T, Funakoshi S, Morihara D, et al. Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective study. Intest Res 2023;21:471–480.

16. Dhaliwal A, Quinlan JI, Overthrow K, et al. Sarcopenia in inflammatory bowel disease: a narrative overview. Nutrients 2021;13:656.

17. Nardone OM, de Sire R, Petito V, et al. Inflammatory bowel diseases and sarcopenia: the role of inflammation and gut microbiota in the development of muscle failure. Front Immunol 2021;12:694217.

18. Li S, Ney M, Eslamparast T, et al. Systematic review of nutrition screening and assessment in inflammatory bowel disease. World J Gastroenterol 2019;25:3823–3837.

19. Kim JH, Oh CM, Yoo JH. Obesity and novel management of inflammatory bowel disease. World J Gastroenterol 2023;29:1779–1794.

20. Kim J. Cardiovascular manifestations in Behçet’s disease. Yonsei Med J 2024;65:493–500.

21. WHO/IASO/IOTF. The Asia-Pacific perspective: redefining obesity and its treatment. Melbourne: Health Communications Australia, 2000. 22. Stabroth-Akil D, Leifeld L, Pfützer R, Morgenstern J, Kruis W. The effect of body weight on the severity and clinical course of ulcerative colitis. Int J Colorectal Dis 2015;30:237–242.

23. Hu Q, Ren J, Li G, Wu X, Li J. The impact of obesity on the clinical course of inflammatory bowel disease: a meta-analysis. Med Sci Monit 2017;23:2599–2606.

24. Lima JS, de Brito CAA, Celani LMS, et al. Body mass index profile of adult patients with inflammatory bowel disease in a multicenter study in northeastern Brazil. Clin Exp Gastroenterol 2023;16:213–224.

25. McKenna NP, Habermann EB, Zielinski MD, Lightner AL, Mathis KL. Body mass index: implications on disease severity and postoperative complications in patients with Crohn’s disease undergoing abdominal surgery. Surgery 2019;166:703–708.

26. Scaldaferri F, Pizzoferrato M, Lopetuso LR, et al. Nutrition and IBD: malnutrition and/or sarcopenia? A practical guide. Gastroenterol Res Pract 2017;2017:8646495.

27. Han SJ, Kang EA, Park J, et al. Risk factors for surgery in patients with intestinal Behçet’s disease during anti-tumor necrosis factor-alpha therapy. Yonsei Med J 2023;64:111–116.

28. Massironi S, Viganò C, Palermo A, et al. Inflammation and malnutrition in inflammatory bowel disease. Lancet Gastroenterol Hepatol 2023;8:579–590.

29. Brown P, Clark T, Dowson G, et al. Relationship of body mass index to clinical outcomes after infliximab therapy in patients with Crohn’s disease. J Crohns Colitis 2016;10:1144–1150.

30. Johnson AM, Harmsen WS, Aniwan S, Tremaine WJ, Abu Dayyeh BK, Loftus EV. Prevalence and impact of obesity on disease-specific outcomes in a population-based cohort of patients with ulcerative colitis. J Crohns Colitis 2021;15:1816–1823.

31. Kurnool S, Nguyen NH, Proudfoot J, et al. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther 2018;47:1472–1479.

32. Kim M, Cho M, Hong S, et al. Weight loss from diagnosis of Crohn’s disease to one year post-diagnosis results in earlier surgery. Sci Rep 2023;13:21101.

33. Bian D, Jiang Y, Gu Y, et al. Body mass index and disease activity are associated with moderate to severe disability in Crohn’s disease: a cross-sectional study in Shanghai. Front Med (Lausanne) 2021;8:662488.

34. Wulan SN, Westerterp KR, Plasqui G. Ethnic differences in body composition and the associated metabolic profile: a comparative study between Asians and Caucasians. Maturitas 2010;65:315–319.

35. Kaazan P, Tan Z, Maiyani P, et al. Weight and BMI patterns in a biologicals-treated IBD cohort. Dig Dis Sci 2022;67:5628–5636.

36. Sehgal P, Su S, Zech J, et al. Visceral adiposity independently predicts time to flare in inflammatory bowel disease but body mass index does not. Inflamm Bowel Dis 2024;30:594–601.

37. Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 2020;21:300–307.e2.

38. Ananthakrishnan AN, Kaplan GG, Bernstein CN, et al.; International Organization for Study of Inflammatory Bowel Diseases. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. Lancet Gastroenterol Hepatol 2022;7:666–678.